384 research outputs found
The Promise of Artificial Intelligence and Potential Impact on the Sales Function
After a great deal of press and promise, artificial intelligence is beginning to make inroads in the sales function. In this paper, we follow on United Kingdom-based company called CloudApps and the firm\u27s development of an artificial intelligence solution to address the issues inherent in the management of the sales pipeline. We then outline some of the other potential applications using artificial intelligence within an organizations\u27 sales function
State of the States 2005
Summarizes major state policy developments in 2004 and projects likely trends for 2005. Includes health care, education, homeland security, tax and budget policy, the same-sex marriage controversy, and profiles of governors elected in November 2004
Hormonal contraceptive use increases serum 25-hydroxyvitamin D concentrations in active, young women [abstract]
Abstract only availableMany studies have shown that the estrogen in oral hormonal contraceptives (HC) increases serum 25-hydroxyvitamin D 25(OH)D concentrations in women. As a hormone that regulates gene transcription estrogen is known to increase Vitamin-D binding protein concentrations, and therefore 25(OH)D concentrations in the blood. Furthermore, Vitamin D is a major regulator of bone metabolism and its status within the blood influences circulating levels of bone turnover markers. The objective of this study was to determine the effects of HC use on serum 25OHD concentrations and biochemical markers of bone turnover in active young females. Thirty-nine young (age 18-33 years), active (≥5 h of aerobic exercise per week) women participated (HC users, n=16; Non-users, n=23). Of the HC users, 9 were taking monophasic HC; 7 were taking triphasic HC. Fasting serum samples were taken during the early follicular phase (d2-5 of the menstrual cycle) and were analyzed for 25OHD and biochemical bone markers [bone alkaline phosphatase (BAP), N-telopeptide of collagen cross-links (NTx), parathyroid hormone (PTH) and osteocalcin (OC)] using radioimmuno assay and ELISA, respectively. Serum 25OHD was significantly greater (p=.007) and BAP significantly lower (p=.002) in HC users compared with nonusers. No differences were found between groups for NTx, PTH or osteocalcin. Serum concentrations of BAP and Vitamin D were negatively correlated (r= -.453; p=.004). We conclude that HC use is associated with increased serum 25OHD concentrations and lower circulating BAP in young active females
Perspectives of scientists on disseminating research findings to non-research audiences
BACKGROUND: Little is known about practices used to disseminate findings to non-research, practitioner audiences. This study describes the perspectives, experience and activities of dissemination & implementation (D&I) scientists around disseminating their research findings.
METHODS: The study explored D&I scientists\u27 experiences and recommendations for assessment of dissemination activities to non-research audiences. Existing list serves were used to recruit scientists. Respondents were asked three open-ended questions on an Internet survey about dissemination activities, recommendations for changing evaluation systems and suggestions to improve their own dissemination of their work.
RESULTS: Surveys were completed by 159 scientists reporting some training, funding and/or publication history in D&I. Three themes emerged across each of the three open-ended questions. Question 1 on evaluation generated the themes of: 1a) promotional review; 1b) funding requirements and 1c) lack of acknowledgement of dissemination activities. Question 2 on recommended changes generated the themes of: 2a) dissemination as a requirement of the academic promotion process; 2b) requirement of dissemination plan and 2c) dissemination metrics. Question 3 on personal changes to improve dissemination generated the themes of: 3a) allocation of resources for dissemination activities; 3b) emerging dissemination channels and 3c) identify and address issues of priority for stakeholders.
CONCLUSIONS: Our findings revealed different types of issues D&I scientists encounter when disseminating findings to clinical, public health or policy audiences and their suggestions to improve the process. Future research should consider key requirements which determine academic promotion and grant funding as an opportunity to expand dissemination efforts
Achieving Quality in Cardiovascular Imaging Proceedings From the American College of Cardiology–Duke University Medical Center Think Tank on Quality in Cardiovascular Imaging
Recommended from our members
Development and Characterization of Boehmite Component Simulant
According to Bechtel National Inc.’s (BNI’s) Test Specification 24590-PTF-TSP-RT-06-006, Rev 0, “Simulant Development to Support the Development and Demonstration of Leaching and Ultrafiltration Pretreatment Processes,” simulants for boehmite, gibbsite, and filtration are to be developed that can be used in subsequent bench and integrated testing of the leaching/filtration processes. These simulants will then be used to demonstrate the leaching process and to help refine processing conditions that may impact safety basis considerations (Smith 2006). This report documents the results of the boehmite simulant development and blended simulant crossflow ultrafiltration leaching completed in accordance with the test plan TP-RPP-WTP-469 Rev 0 (WTP Doc. No. 24590- 101-TSA-W000-0004-182-00001 Rev 00A) prepared and approved in response to the cited test specification. This report also includes the results of the aluminate and anion effect on boehmite dissolution performed in accordance with the test plan TP-RPP-WTP-509, Rev 0 (WTP Doc. No. 24590-101-TSA-W000-0004-72-00019 Rev 00A) prepared and approved in response to the Test Specification 24590-WTP-TSP-RT-07-004, Rev 0 (Sundar 2007)
Future Directions for Cardiovascular Disease Comparative Effectiveness Research Report of a Workshop Sponsored by the National Heart, Lung, and Blood Institute
Comparative effectiveness research (CER) aims to provide decision makers with the evidence needed to evaluate the benefits and harms of alternative clinical management strategies. CER has become a national priority, with considerable new research funding allocated. Cardiovascular disease is a priority area for CER. This workshop report provides an overview of CER methods, with an emphasis on practical clinical trials and observational treatment comparisons. The report also details recommendations to the National Heart, Lung, and Blood Institute for a new framework for evidence development to foster cardiovascular CER, and specific studies to address 8 clinical issues identified by the Institute of Medicine as high priorities for cardiovascular CER
Increased Mortality among Survivors of Myocardial Infarction with Kidney Dysfunction: the Contribution of Gaps in the use of Guideline-Based Therapies
Abstract
Background
We assessed the degree to which differences in guideline-based medical therapy for acute myocardial infarction (AMI) contribute to the higher mortality associated with kidney disease.
Methods
In the PREMIER registry, we evaluated patients from 19 US centers surviving AMI. Cox regression evaluated the association between estimated glomerular filtration rate (GFR) and time to death over two years, adjusting for demographic and clinical variables. The contribution of variation in guideline-based medical therapy to differences in mortality was then assessed by evaluating the incremental change in the hazard ratios after further adjustment for therapy.
Results
Of 2426 patients, 26% had GFR ≥ 90, 44% had GFR = 60- < 90, 22% had GFR = 30- < 60, and 8% had GFR < 30 ml/min/1.73 m2. Greater degrees of renal dysfunction were associated with greater 2-year mortality and lower rates of guideline-based therapy among eligible patients. For patients with severely decreased GFR, adjustment for differences in guideline-based therapy did not significantly attenuate the relationship with mortality (HR 3.82, 95% CI 2.39–6.11 partially adjusted; HR = 3.90, 95% CI 2.42–6.28 after adjustment for treatment differences).
Conclusion
Higher mortality associated with reduced GFR after AMI is not accounted for by differences in treatment factors, underscoring the need for novel therapies specifically targeting the pathophysiological abnormalities associated with kidney dysfunction to improve survival.Peer Reviewe
Multiyear Surveillance for Avian Influenza Virus in Waterfowl from Wintering Grounds, Texas Coast, USA
This surveillance can help in assessments of the prevalence of wild animal-to-human transmission
- …